Biobanking Market Size & Growth Forecast 2027–2036, By Segments (Application, Product & Service, End-User, Sample Type, Storage Type), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Biobanking Market size was worth USD 87.33 Billion in 2026 and is expected to grow at 8.59% CAGR between 2027 and 2036, crossing USD 199.1 Billion by 2036. The industry revenue for 2027 is assessed at USD 93.7 Billion.

• Base Year Value (2026): USD 87.33 Billion
• CAGR (2027-2036): 8.59%
• Forecast Year Value (2036): USD 199.1 Billion
• Historical Data Period: 2022-2026
• Largest Region: North America
• Forecast Period: 2027-2036

Biobanking Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America held 48.44% in 2025, backed by advanced biomedical research, healthcare infrastructure, established research institutions, and growing precision medicine and genomics activity.
  • Asia Pacific is expected to grow fastest as healthcare infrastructure, life sciences investment, precision medicine, genomics, and biomedical research capabilities expand.

• Segment Momentum:

  • Regenerative medicine held 55.54% of the market in 2025 as preserved biological specimens are essential for developing cell- and tissue-based therapies, supporting translational research and personalized medicine initiatives.
  • Software is the fastest-growing segment because biobanks increasingly require digital platforms for sample tracking, inventory management, data integration, and regulatory compliance as specimen collections continue to grow.

• Market Expansion Drivers:

  • Advancing genomics and drug development accelerating biobank sample utilization
  • Rising personalized medicine demand increasing long-term biospecimen storage needs
  • Expansion of population-scale genomic databases supporting precision medicine ecosystems

• Leading Market Participants:

  Prominent companies in the biobanking market include Thermo Fisher Scientific Inc. (United States), Azenta, Inc. (United States), Avantor, Inc. (United States), Becton, Dickinson and Company (United States), Cryoport, Inc. (United States), Eurofins Scientific SE (Luxembourg), QIAGEN N.V. (Netherlands), Charles River Laboratories International, Inc. (United States), PHC Holdings Corporation (Japan), STEMCELL Technologies Inc. (Canada)

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2026 Market Size: USD 87.33 Billion
  • 2027 Estimated Market Size: USD 93.7 Billion
  • Projected Market Size: USD 199.1 Billion by 2036
  • Growth Forecasts: 8.59% CAGR (2027-2036)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Regenerative Medicine (Application) | Equipment (Product & Service) | Biotechnology & Pharmaceutical Companies (End-User) | Blood Products (Sample Type) | Manual Storage (Storage Type)
  • Emerging Opportunity Segment: Clinical Research (Application) | Software (Product & Service) | Contract Research Organizations (CROs) (End-User) | Nucleic Acids (Sample Type) | Automated Storage (Storage Type)

Market Growth Drivers and Industry Trends

Advancing genomics and drug development accelerating biobank sample utilization

Rapid progress in genomics research and pharmaceutical innovation is significantly increasing the need for well-characterized biological samples, which will drive the biobanking market growth. Biobanks provide researchers with standardized, high-quality biospecimens that support genomic sequencing, biomarker discovery, and translational research across a broad range of therapeutic areas. As drug developers increasingly rely on genetic and molecular insights to improve target identification and validate treatment responses, the demand for reliable sample repositories continues to expand. Enhanced sample annotation, quality control protocols, and integrated data management systems further improve the scientific value of stored specimens for both academic and commercial research programs.

Rising personalized medicine demand increasing long-term biospecimen storage needs

The growing emphasis on individualized healthcare is creating sustained demand for long-term preservation of biological materials, and the biobanking market is benefiting from this transformation in clinical practice. Personalized medicine depends on access to patient-specific biospecimens that enable disease profiling, treatment selection, and ongoing clinical research based on genetic and molecular characteristics. Healthcare institutions and research organizations are expanding storage infrastructure to preserve blood, tissue, DNA, and other biological materials under standardized conditions that maintain sample integrity over extended periods. This long-term preservation supports future diagnostic advancements, clinical studies, and precision treatment strategies while ensuring the availability of valuable biological resources.

Expansion of population-scale genomic databases supporting precision medicine ecosystems

The development of large-scale genomic databases is strengthening collaborative research and accelerating precision healthcare initiatives, a trend expected to propel the biobanking market growth. Population-wide biobanking programs collect diverse biospecimens linked with clinical and genetic information, creating comprehensive resources for studying disease patterns, genetic variation, and treatment outcomes across different populations. These extensive repositories enable researchers to identify novel biomarkers, improve disease risk assessment, and support the development of more targeted therapeutic interventions. Growing collaboration among healthcare providers, research institutions, and public health organizations is also increasing the need for standardized sample collection, secure storage, and interoperable data management frameworks.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Advancing genomics and drug development accelerating biobank sample utilization	2%	High	North America, Europe	High	Mid Term
Rising personalized medicine demand increasing long-term biospecimen storage needs	1.8%	Moderate	North America, Asia Pacific	High	Mid Term
Expansion of population-scale genomic databases supporting precision medicine ecosystems	1.5%	Moderate	Europe, Asia Pacific	Emerging	Long Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America accounted for the largest share of the biobanking market, reaching 48.44% in 2026. The region's strong position is supported by an advanced biomedical research ecosystem, substantial healthcare infrastructure, and increasing use of biological samples in disease research, drug development, and precision medicine. Growing emphasis on genomics and personalized healthcare is increasing the need for well-organized biological sample storage and management capabilities. In addition, established research institutions and clinical networks are facilitating the collection, preservation, and utilization of high-quality specimens, while increasing research activity in chronic and complex diseases continues to support biobanking requirements.

Asia Pacific is anticipated to experience the fastest growth, supported by expanding healthcare and research infrastructure, rising investments in life sciences, and increasing adoption of precision medicine approaches. Growing research activity across emerging healthcare markets is creating greater demand for systematic collection and long-term preservation of biological samples. Governments and research organizations are also placing greater emphasis on strengthening biomedical capabilities and developing advanced healthcare systems. Moreover, the increasing focus on genomics, clinical research, and innovative therapeutic development is encouraging the establishment and modernization of biobanking facilities, creating favorable conditions for regional market expansion.

No card data available for this language/report.

Segment Leadership and Growth Trends

 

Application Segment Analysis: Regenerative Medicine (Largest Segment) vs Clinical Research (Fastest-Growing Segment)

Regenerative medicine dominated the biobanking market with a 55.54% share in 2026, reflecting the growing importance of preserved biological specimens for developing advanced cell- and tissue-based therapies. Biobanks play a critical role in maintaining high-quality biological materials that support regenerative treatment development, translational research, and personalized medicine initiatives. Expanding interest in tissue engineering and stem cell applications continues to strengthen demand for specialized biobanking infrastructure.

Clinical research is expected to register the fastest growth as the volume of clinical studies requiring standardized biological samples continues to expand. Increasing emphasis on precision medicine, biomarker discovery, and evidence-based therapeutic development is driving greater utilization of biobanking services throughout the clinical research process. Broader collaboration between research institutions, healthcare organizations, and life science companies is further supporting this segment's expansion.

Product & Service Segment Analysis: Equipment (Largest Segment) vs Software (Fastest-Growing Segment)

Equipment accounted for the largest share of the biobanking market at 45.05% in 2026, supported by the essential requirement for reliable storage, preservation, and sample handling systems. Advanced freezers, cryogenic storage solutions, monitoring systems, and laboratory equipment are fundamental to maintaining specimen integrity throughout long-term storage. Continued expansion of biobank facilities and increasing sample volumes sustain demand for sophisticated equipment.

The software segment is anticipated to grow at the fastest pace due to rising requirements for efficient sample tracking, digital inventory management, and secure data integration. As biobanks manage increasingly complex datasets and larger specimen collections, software platforms are becoming indispensable for improving operational efficiency, regulatory compliance, and collaboration across research networks.

End-User Segment Analysis: Biotechnology & Pharmaceutical Companies (Largest Segment) vs Contract Research Organizations (CROs) (Fastest-Growing Segment)

Holding the largest share of the biobanking market, biotechnology & pharmaceutical companies accounted for 45.16% in 2026, driven by their extensive reliance on high-quality biological samples throughout drug discovery, biomarker identification, and therapeutic development. Access to well-characterized specimens enables more efficient research workflows, supports precision medicine initiatives, and accelerates the development of innovative treatments, reinforcing the segment's leadership.

Contract research organizations (CROs) are emerging as the fastest-growing end-user segment as pharmaceutical and biotechnology companies increasingly outsource research activities to improve efficiency and optimize development timelines. Growing demand for specialized clinical research services, coupled with expanding collaborative research models, is increasing reliance on CROs with advanced biobanking capabilities to support complex preclinical and clinical programs.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Application	Regenerative Medicine, Life-science Research, Clinical Research	Regenerative Medicine	Clinical Research
Product & Service	Equipment, Consumable, Service, Software	Equipment	Software
End-User	Biotechnology & Pharmaceutical Companies, Contract Research Organizations (CROs), Academic & Research Institutes, Hospitals	Biotechnology & Pharmaceutical Companies	Contract Research Organizations (CROs)
Sample Type	Blood Products, Human Tissues, Cell Lines, Nucleic Acids, Biological Fluids, Human Waste Products	Blood Products	Nucleic Acids
Storage Type	Automated Storage, Manual Storage	Manual Storage	Automated Storage

Competitive Landscape and Market Positioning

Leading companies in the biobanking market:

1. Thermo Fisher Scientific, Inc. (United States)
2. Azenta, Inc. (United States)
3. Avantor, Inc. (United States)
4. Becton Dickinson and Company (United States)
5. Cryoport, Inc. (United States)
6. Eurofins Scientific SE (Luxembourg)
7. QIAGEN N.V. (Netherlands)
8. Charles River Laboratories International, Inc. (United States)
9. PHC Holdings Corporation (Japan)
10. STEMCELL Technologies, Inc. (Canada)

The biobanking market is evolving around the ability to deliver high-quality biological specimens supported by rigorous data management and standardized preservation practices. Organizations are investing in advanced storage infrastructure, digital sample tracking, and automated handling systems to improve reproducibility and strengthen confidence among research and clinical users. Competitive differentiation is also extending beyond storage capacity to include integrated informatics, traceability, and regulatory compliance that simplify collaboration across research institutions and healthcare organizations. As demand grows for precision medicine and translational research, providers capable of maintaining sample integrity while enabling efficient data accessibility are gaining a stronger competitive position in an increasingly interconnected research ecosystem.

Industry Development/News

Company Name	Date	Key Development
Abu Dhabi Biobank	Jun-26	Abu Dhabi Biobank entered into a technology partnership with BioTwin to integrate artificial intelligence into preventive healthcare frameworks. The collaboration focuses on leveraging biobanking assets for AI-driven multi-cancer screening and personalized medicine workflows, advancing digital transformation in the regional healthcare market.
Colossal Biosciences	Jun-26	Colossal Biosciences partnered with the U.S. Fish and Wildlife Service to establish the BioVault initiative. This specialized biological depository focuses on the conservation of endangered species through standardized cryopreservation of biological samples, establishing a structured biomaterial reserve for long-term biodiversity preservation.
Abu Dhabi Biobank	May-26	Abu Dhabi Biobank established a strategic collaboration with Human Life CORD Japan to accelerate the clinical adoption of umbilical cord-derived stem cell therapies. The partnership focuses on localizing manufacturing capabilities and clinical application protocols within the UAE, advancing regional regenerative medicine infrastructure.
SciSafe	Oct-25	SciSafe executed an infrastructure expansion at its biorepository facility in East Brunswick, New Jersey, significantly increasing its ultra-low temperature cold chain and biological storage capacities. The operational scaling enhances the company's logistical footprint, securing increased market capacity for clinical trial logistics and long-term specimen preservation.
Abu Dhabi Biobank	Oct-25	Abu Dhabi Biobank partnered with NMC Healthcare to integrate public and private cord blood banking services across UAE hospital networks. This collaborative initiative scales the biobank's clinical collection infrastructure, expanding its long-term operational footprint and strengthening regional biomedical research capabilities.
Abu Dhabi Biobank	Oct-25	Abu Dhabi Biobank entered into a strategic precision medicine partnership with AstraZeneca to accelerate translational research workflows. The collaboration utilizes established biobanking resources and deep clinical research capabilities to improve the translation of multi-omic data into targeted clinical healthcare applications.
National Institute of Animal Biotechnology (NIAB)	Aug-25	The National Institute of Animal Biotechnology inaugurated India’s primary animal stem cell biobank and specialized laboratory facility in Hyderabad. The new infrastructure provides standardized biological storage to support veterinary stem cell research and commercial cellular agriculture initiatives, including cultivated meat development.
TTAM Research Institute	Jul-25	TTAM Research Institute completed the strategic acquisition of 23andMe's assets, including its extensive biobank, personal genome service, and total health research operations. This transaction directly expands the institute's access to genomic datasets, accelerating its proprietary biobanking infrastructure and genetics-driven pharmaceutical development programs.
M42	Apr-25	M42 executed a strategic investment and commercial partnership with Juvenescence to accelerate the development of therapeutics for age-related conditions. The collaboration bridges healthcare delivery with advanced biotechnology, establishing a longevity research framework that leverages specialized biological datasets and clinical translation networks.
SPT Labtech	Jan-21	SPT Labtech finalized the strategic acquisition of Apricot Designs to expand its laboratory liquid handling portfolio. This integration strengthens the company's competitive positioning in automated laboratory instrumentation, scaling up its capability to support high-throughput life sciences research and automated biobanking workflows.